Unlike zoledronic acid, which is administered intravenously and can potentially affect renal function, denosumab is given subcutaneously and does not affect kidney function, he said; as such, it represents a "novel treatment option."
The updated NCCN prostate cancer guidelines are available at www.nccn.org. Dr. Mohler is a cofounder and chief medical officer of AndroBioSys Inc. in Buffalo, N.Y.